Momelotinib (CYT387) , Orphan Drug JAK Inhibitor for Targeted Therapy

Momelotinib (CYT387) is a promising JAK inhibitor, primarily developed for the treatment of myelofibrosis and related hematologic disorders. It works by selectively inhibiting the JAK1 and JAK2 pathways, helping to reduce disease symptoms and improve patient outcomes. As an orphan drug, Momelotinib addresses unmet medical needs in rare conditions, offering new hope to affected patients. Shanghai Lizhuo Pharmaceutical Technology Co., Ltd., a leading China-based manufacturer, supplier, and factory, proudly produces high-quality Momelotinib. With advanced production facilities and stringent quality control, Shanghai Lizhuo Pharmaceutical ensures the consistent supply of this innovative compound to global markets. Their dedication to pharmaceutical excellence and compliance with international standards positions them as a trusted partner in the development and distribution of cutting-edge JAK inhibitors like Momelotinib.

Related Products